State of Wisconsin Investment Board Invests $181,000 in Concert Pharmaceuticals, Inc. (CNCE) Stock
State of Wisconsin Investment Board acquired a new position in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 13,000 shares of the biotechnology company’s stock, valued at approximately $181,000. State of Wisconsin Investment Board owned about 0.06% of Concert Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors and hedge funds have also recently made changes to their positions in CNCE. Driehaus Capital Management LLC purchased a new stake in Concert Pharmaceuticals in the 1st quarter worth about $7,353,000. Lyon Street Capital LLC purchased a new stake in Concert Pharmaceuticals in the 1st quarter worth about $1,467,000. Paulson & CO. Inc. purchased a new stake in Concert Pharmaceuticals in the 1st quarter worth about $1,198,000. KCG Holdings Inc. purchased a new stake in Concert Pharmaceuticals in the 1st quarter worth about $1,141,000. Finally, Prudential Financial Inc. increased its holdings in Concert Pharmaceuticals by 26.2% in the 1st quarter. Prudential Financial Inc. now owns 253,130 shares of the biotechnology company’s stock worth $4,319,000 after acquiring an additional 52,500 shares during the last quarter. 62.37% of the stock is owned by institutional investors.
Concert Pharmaceuticals, Inc. (NASDAQ CNCE) opened at 14.58 on Friday. Concert Pharmaceuticals, Inc. has a 12-month low of $7.11 and a 12-month high of $19.11. The stock’s market cap is $330.78 million. The firm’s 50-day moving average price is $14.61 and its 200-day moving average price is $14.82.
Concert Pharmaceuticals (NASDAQ:CNCE) last issued its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.58) EPS for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.04. The business had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.20 million. Concert Pharmaceuticals had a negative return on equity of 61.98% and a negative net margin of 60,681.70%. On average, equities analysts predict that Concert Pharmaceuticals, Inc. will post ($2.18) EPS for the current fiscal year.
CNCE has been the subject of several recent research reports. HC Wainwright initiated coverage on Concert Pharmaceuticals in a report on Monday, July 24th. They issued a “buy” rating and a $20.00 price objective for the company. Zacks Investment Research raised Concert Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, August 10th. ValuEngine raised Concert Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Aegis reaffirmed a “buy” rating and set a $25.00 target price on shares of Concert Pharmaceuticals in a report on Monday, June 12th. Finally, BidaskClub lowered Concert Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, July 12th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $24.80.
About Concert Pharmaceuticals
Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas.
Receive News & Ratings for Concert Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.